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Abstract 
The canine transmissible venereal tumour (CTVT) is a transmissible cancer that is 
spread between dogs by the allogeneic transfer of living cancer cells. The infectious 
agents in CTVT are the living cancer cells themselves, which are transmitted 
between dogs during coitus. CTVT first arose several thousand years ago and the 
disease has a global distribution and is frequently observed in dogs from Brazil. We 
evaluated the utility of a LINE-MYC quantitative PCR for diagnosis of CTVT cases in 
Brazil. Our analysis indicated that the LINE-MYC rearrangement was detectable in all 
CTVT samples but not in their corresponding hosts. This genetic assay proves to be 
a useful tool for providing a definitive molecular diagnosis of CTVT, which presents 
with varying degrees of aggressiveness and invasiveness in different host dogs and 
can therefore be a diagnostic challenge in some specific cases. 
Keywords: Canine transmissible venereal tumour, transmissible cancer, oncology, 
molecular diagnosis, LINE-MYC. 
 
 
Introduction 
 The canine transmissible venereal tumour (CTVT) is a naturally occurring 
transmissible cancer that affects the external genitalia of both male and female dogs. 
The disease is spread by the allogeneic transfer of living cancer cells mainly during 
coitus but also through licking, biting and scratching.1,2,3 CTVT is the oldest known 
mammalian somatic cell lineage and genetic studies indicate that it originated more 
than 10,000 years ago.4,5,6 Rather than dying together with its original host, the cells 
of this specific cancer are still alive today through acquiring adaptations for cell 
transmission between hosts and for survival as an allogeneic graft.3 CTVT is 
frequently observed in dogs from Brazil, however, this disease has a global 
distribution and has been documented to be present in at least 90 countries on all six 
inhabited continents and its distribution is linked to the presence of free-roaming 
dogs.7 Important evidence for clonal transmission of CTVT was provided by the 
identification of a genomic rearrangement involving the insertion of a repetitive 1.5kb 
DNA segment derived from a long interspersed nuclear element (LINE) upstream of 
the first exon of the c-myc gene.8  This genomic rearrangement has been identified in 
a large set of globally distributed CTVT tumors, but it has not been found in normal 
dogs, and it is considered to be diagnostic evidence for CTVT.4,5,9,10,11,12,13,14,15,16 It is 
possible that this rearrangement was present in the germline of the CTVT founder 
(i.e. the animal from whose somatic cells CTVT first emerged), that it occurred 
somatically during the development of the founding CTVT tumour, or that it occurred 
somatically in a CTVT clone that has subsequently achieved global distribution. 17 
The purpose of this study was to evaluate the utility of a LINE-MYC quantitative PCR 
(qPCR) for diagnosis of CTVT cases in Brazil. 
 
Materials and Methods 
Tumour and blood specimens 
 Samples were obtained from 20 unrelated dogs with spontaneous CTVT 
diagnosed at the Veterinary Hospital ”Dr Halim Atique” - Centro Universitário de Rio 
Preto (UNIRP), São José do Rio Preto, São Paulo, Brazil. The dogs were of different 
breeds, age and sex, as specified in Table 1. Tumour samples with an average size 
of 1 cm3 were collected by surgical excision from all 20 dogs and immediately 
stabilised by freezing in liquid nitrogen. These samples were collected before starting 
chemotherapy treatment. Two to five mililitres of peripheral blood were also collected 
from 17 of these dogs and mixed immediately with RNAlater solution in the 
proportion of 1:3 (Blood: RNAlater solution). This study was approved by the Animal 
Research Ethics Committee of the São Paulo State University at Jaboticabal, São 
Paulo, Brazil, under protocol number 24674/2012. 
Genomic DNA extraction 
 DNeasy blood & tissue kit® (Qiagen - product number 69506) was used to 
extract genomic DNA from both blood and tumour tissue according to the 
manufacturer’s protocol. The DNA was quantified using a Nanodrop ND-1000 
spectrophotometer and Qubit® assay (Life technologies - product number Q32851) 
Quantitative PCR 
 The quantitative PCR (qPCR) was performed with two primer sets (see Table 
2): one primer set was specific for B-ACTIN, and was used as a control for 
normalization; the second pair of primers spanned the LINE-MYC rearrangement 
junction, and their product is thus specific to CTVT. 18 The qPCR was performed with 
SYBR® Green Mix (Life Technologies – product number 4312704) with conditions 
described in Tables 3 and 4. qPCR was performed using an Applied Biosystems 
7900HT Fast Real-Time PCR system. Standard curves for LINE-MYC and B-ACTIN 
were generated using a CTVT sample, 29T. Relative LINE-MYC and B-ACTIN 
amplification values were estimated for each sample using the standard curve.  
Results 
LINE-MYC rearrangement 
 In order to confirm the CTVT status of all 20 samples, qPCR was performed 
for the LINE-MYC rearrangement. This procedure was conducted with CTVT and 
host samples. Results showed that the LINE-MYC rearrangement was detectable in 
all 20 (20/20) CTVT samples but not in their corresponding hosts (0/17) (Figure 1A 
and 1B). The mean LINE-MYC:B-ACTIN ratio was 1.2527 in tumours and 0.0002 in 
hosts. 
Discussion/Conclusion 
 CTVT represents the oldest known malignant cell in continuous propagation 
whereby a single malignant clone of cells has colonized dogs worldwide. Clinical 
history, signalment and cytological/histological features are often sufficient for 
diagnosis of CTVT. However, molecular biology can also be helpful in cases with an 
atypical presentation. The identification of a LINE element insertion near the MYC 
locus in the CTVT genome by PCR amplification is of diagnostic importance. The 
presence of detectable levels of LINE-MYC rearrangement observed in all CTVT 
samples and absence in their corresponding hosts confirm that this assay provided a 
diagnosis of CTVT. Our findings support published data indicating that the LINE-MYC 
rearrangement is conserved in CTVT and can be used clinically as a definitive 
diagnosis of CTVT. 4,5,19 The variation in observed LINE-MYC:B-ACTIN DNA ratios 
between tumours identified in this study is probably due to to variable levels of 
normal host cells present in tumours; however, it is also possible that there is 
variation in LINE-MYC and/ or B-ACTIN copy number between tumours. It will be 
important to determine the limit of sensitivity of this assay to detect CTVT tumours 
with a high proportion of host cells. The mean ratio of LINE-MYC to B-ACTIN in 
CTVT tumours was 1.2527, and probably reflects non-diploid copy number of LINE-
MYC and/or B-ACTIN in CTVT tumours, together with the presence of host cells. 
Molecular diagnosis of CTVT may be particularly useful in cases of CTVT with 
atypical presentation. For instance, CTVT with extragenital occurrence and 
generalised metastases, often become a diagnostic and clinical challenge, as it may 
be difficult to distinguish between CTVT and other canine round cell neoplasms. This 
genetic assay may, therefore, prove to be a very useful tool for providing a definitive 
diagnosis in these cases. In conclusion, as a specific molecular alteration in CTVT, 
the rearrangement of LINE-MYC was also identified in CTVT cells in dogs from Brazil 
and this genetic assay can be useful as definitive diagnosis of CTVT.  
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 Table 1. Summary of samples used in this study. Tumour tissue was collected from all 20 
animals; matched blood was collected from 17 animals. 
Sample Breed Sex Age (years) Tumour location 
1 Pit Bull F 2 Vagina 
2 Mixed F 10 Vagina 
3 Mixed M 4 Penis 
4 Mixed F 5 Vagina 
5 Mixed F 3 Vagina 
6 Mixed F 5 Vagina 
7 Mixed M 4 Penis 
8 Mixed F 5 Vagina 
9 Shih Tzu F 4 Vagina 
10 Border Collie F 4 Vulva/Vagina 
11 Shih Tzu F 7 Vagina 
12 Mixed M 3 Penis 
13 Mixed F 6 Vagina 
14 Mixed F 4 Vulva/Vagina 
15 Mixed M 3 Penis 
16 Poodle F 4 Vagina 
17 Mixed M 5 Penis 
18 Mixed F 5 Vagina 
19 Mixed M 4 Nasal cavity 
20 Border Collie M 3 Penis/Prepuce/Eyelid 
 
Table 2. Primer sequences for qPCR of LINE-MYC and B-ACTIN. 
 Forward Reverse 
B- ACTIN CTCCATCATGAAGTGTGACGTTG CGATGATCTTGATCTTCATTGTGC 
LINE-MYC AGGGTTTCCCATCCTTTAACATT AGATAAGAAGCTTTTGCACAGCAA 
 
 
 Table 3. qPCR reaction conditions. 
qPCR Reagent Volume per 
reaction 
SYBR Green Mix   10uL 
Primers (5uM/primer) 2.4uL 
gDNA (20ng/ul) 0.5uL 
Water 7.1uL 
Total volume 20uL 
 
 
Table 4. qPCR amplification conditions* 
Stage Temperature (ºC) Time 
Initial denaturation 95 10 minutes 
40 cycles 95 15 seconds 
 60 60 seconds 
*Fluorescence was detected each cycle 
 
 
 
 
 
 
 
 
 
 
Figure 1. The bars represent LINE-MYC:B-ACTIN DNA ratio measured by qPCR in 
tumours (red) and hosts (blue). The LINE-MYC rearrangement was (A) detectable in 
all 20 CTVT samples and (B) absent in all hosts. Missing data from some hosts due 
to unavailability of samples are represented by absence of label (5, 7 and 12). 
 
 
